Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Update on squamous cell carcinoma of the head and neck

Update on squamous cell carcinoma of the head and neck At the annual ASCO meeting clinically relevant data concerning the management of advanced head and neck cancer that will influence clinical practice in the future were presented. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Update on squamous cell carcinoma of the head and neck

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/update-on-squamous-cell-carcinoma-of-the-head-and-neck-mRdZ3cylnD
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0358-9
Publisher site
See Article on Publisher Site

Abstract

At the annual ASCO meeting clinically relevant data concerning the management of advanced head and neck cancer that will influence clinical practice in the future were presented.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Oct 20, 2017

References

  • Global and national burden of diseases and injuries among children and adolescents between 1990 and 2013: findings from the global burden of disease 2013 study
    Kyu, HH; Pinho, C; Wagner, JA; Brown, JC; Bertozzi-Villa, A
  • Development and validation of a staging system for HPV-related oropharyngeal cancer by the international collaboration on Oropharyngeal cancer network for staging (ICON-S): A multicentre cohort study
    O’Sullivan, B; Huang, SH; Su, J; Garden, AS; Sturgis, EM; Dahlstrom, K
  • Head and neck cancer
    Argiris, A; Karamouzis, MV; Raben, D; Ferris, RL
  • Platinum-based chemotherapy plus cetuximab in head and neck cancer
    Vermorken, JB; Mesia, R; Rivera, F; Remenar, E; Kawecki, A; Rottey, S
  • Nivolumab for recurrent squamous-cell carcinoma of the head and neck
    Ferris, RL; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; Licitra, L
  • Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
    Seiwert, TY; Burtness, B; Mehra, R; Weiss, J; Berger, R; Eder, JP
  • Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): An open-label, randomised phase 3 trial
    Machiels, JP; Haddad, RI; Fayette, J; Licitra, LF; Tahara, M; Vermorken, JB
  • LUX-Head and Neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation in patients with primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck
    Burtness, B; Haddad, R; Dinis, J; Trigo, PJM; Yokota, T; Souza Viana, L
  • W3W phase III randomized trial comparing weekly versus three-weekly cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer
    Noronha, V; Joshi, A; Patil, VM; Agarwal, J; Laskar, SG; Budrukkar, AN
  • Safety of pembrolizumab with chemoradiation (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN)
    Powell, SF; Gitau, MG; Sumey, CJ; Reynolds, JT; Lohr, M; McGraw, S
  • Neoadjuvant pembrolizumab in surgically resectable, HPV negative, locally advanced head and neck squamous cell carcinoma (HNSCC)
    Uppaluri, R; Zolkind, P; Lin, T; Nussenbaum, B; Jackson, R; Rich, J
  • Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) wit recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research group trial
    Argiris, A; Li, S; Savvides, P; Ohr, J; Gilbert, J; Levine, MA
  • Genomic Determinants of Response to Pembrolizumab in Head and Neck Squamous Cell Carcinoma
    Haddad, R; Seiwert, TY; Chow, LQ; Gupta, T; Weiss, J; Gluck, I
  • Epacadostat plus pembrolizumab in patients with SCCHN: Preliminary phase 1/2 results from ECHO-202/Keynote-037
    Hamid, O; Bauer, TM; Spira, AI; Olszanski, AJ; Patel, SP; Wasser, JS
  • Targeting the indoleamine 2,3-dioxygenase pathway in cancer
    Moon, YW; Hajjar, J; Hqu, P; Naing, A